PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

22 6 2022 07:00:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

16 6 2022 07:00:02 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

15 6 2022 15:01:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference

18 5 2022 10:15:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

11 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

09 5 2022 15:05:01 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809

05 5 2022 07:00:03 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis

03 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference

02 5 2022 07:00:03 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Needham Healthcare Conference

05 4 2022 07:03:00 提供 Nasdaq GlobeNewswire

CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

28 2 2022 18:43:43 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

28 2 2022 15:05:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers

28 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

24 2 2022 16:41:07 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

24 2 2022 07:03:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

11 1 2022 07:03:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

21 12 2021 07:06:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

18 11 2021 07:00:02 提供 Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results

09 11 2021 15:06:00 提供 Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Piper Sandler Lung Day

07 10 2021 07:06:00 提供 Nasdaq GlobeNewswire